You are invited to watch this webinar, June 11, 2019 (noon to 1 pm, PST) in person or online, presented by Helen Brown, PhD RN, "Work 2 Give: Indigenous and Participatory Knowledge Translation within a Prison-Community Partnership Study" at https://bcsupportunit.ca/events-training/work-2-give-indigenous-and-participatory-knowledge-translation-within-prison OR http://www.providenceresearch.ca/sites/default/files/KT%20CoP%20invite%202019Jun11.pdf
Helen Br
In a 1200 word report issued June 3, 2019, Canada’s federal government acknowledged a horrifying statistic: Canada's Indigenous women are at least six times more likely to become victims of homicide than non-Indigenous women:
https://www.cbc.ca/news/politics/mmiwg-inquiry-deliver-final-report-justice-reforms-1.5158223
In addition, we should acknowledge that Canada's Indigenous people are at least five times more at risk of acquiring hepatitis C, and that
Twice a year HepCBC's all-volunteer outreach team visits the Community Resource Expo (CRE) events held in BC's federal prisons to give the most recent information about viral hepatitis (B and C) care and prevention, and to offer support to those seeking treatment. To see profiles of these institutions, go to
https://www.csc-scc.gc.ca/institutions/001002-5000-eng.shtml
Our all-volunteer team consists of Leon Anderson, Ron Larsen, Dr. Sofia Bartlett, Chery
Is it possible to ELIMINATE HEPATITIS C in Canada? Dr. Jordan Feld presents the BLUEPRINT: "Blueprint to inform hepatitis C elimination efforts in Canada" at CanHepC's launch session, May 24, 2019
Dr Jordan Feld presents the Blueprint to inform hepatitis C elimination efforts in Canada at the 8th Canadian Symposium on Hepatitis C Virus/Canadian Liver Meeting on May 24th, 2019 in Montreal. Watch and share this moving one-hour presentation at https://www.
Links follow to some really amazing "lived experience" stories from the recent UK inquiry, by British people who contracted hepatitis C from contaminated blood products and transfusions, including some stories from their families. They have waited many years for these hearings.
https://www.bbc.com/news/topics/c6gz70808ext/uk-contaminated-blood-scandal
FDA approves MAVYRET™, the first treatment for all genotypes of hepatitis C approved by this US agency for pediatric use. On behalf of Canada's children, we hope Canada will soon follow (Canada's version of AbbVie's hepatitis C drug is spelled Maviret™)!
For Immediate Release, April 30, 2019
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients
Clinical Care Options presents a new "Interactive Decision Support Tool" for Hepatitis B consultations to help determine whether and how to treat HBV patients, "Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV"
Downloading this tool is FREE but requires that you register with Clinical Care Options website:
https://www.clinicaloptions.com/hepatitis/programs/2019-hbv-management/idst/tool
Source: B
Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV:
Men Who Have Sex with Men [MSM] - ACCESS INFORMATION BELOW
Persons Who Inject Drugs [PWID] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and
People Who Are Incarcerated [COMING SOON]
The MSM module is introduced below...
CCO CME/CE-certified interactive video module
Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV:
Persons Who Inject Drugs, [PWID] - ACCESS INFORMATION BELOW.
Men Who Have Sex with Men [MSM] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and
People Who Are Incarcerated [COMING SOON]
The PWID module is introduced below...
CCO CME/CE-certified interactive video modu
Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...
